Yonsei Med J.  2005 Aug;46(4):484-490. 10.3349/ymj.2005.46.4.484.

Characteristics of Type 2 Diabetes in Terms of Insulin Resistance in Korea

• Park JS
• Kim CS
• Nam JY
• Kim DM
• Jo MH
• Park J
• Ahn CW
• Cha BS
• Lim SK
• Kim KR
• Lee HC
• Huh KB

• KMID: 1716517
• DOI: http://doi.org/10.3349/ymj.2005.46.4.484

Abstract

The aim of this study was to assess the implications of insulin resistance on the clinical and biochemical profiles of Korean type 2 diabetic patients. 122 patients with type 2 diabetes underwent a short insulin tolerance test to assess insulin resistance. Subjects were classified in tertiles according to ISI (insulin sensitivity index), and the tertile I (the insulin- resistant group) and tertile III (the insulin-sensitive group) clinical and biochemical parameters were compared. Age, waist circumference (WC), systolic blood pressure (SBP), HbA1c, body fat content, and fasting plasma glucose were significantly higher in tertile I than tertile III (all p < 0.05). The frequency of hypertension and family history of cerebrovascular disease (CVD) were greater in tertile I than III (p < 0.05). To evaluate the factors affecting ISI, multiple regression was performed, and age, WC, SBP, HbA1c, and body fat content were found to be independently related to insulin resistance (p < 0.05). Old age, hypertension, central obesity, and poor glycemic control were identified as clinical parameters of insulin resistance in Korean type 2 diabetic patients.

Keyword

Insulin resistance; type 2 diabetes; Korea

MeSH Terms

Adult
Aged
Blood Glucose/analysis
C-Peptide/analysis
Diabetes Mellitus, Type 2/*metabolism
Female
Hemoglobin A, Glycosylated/analysis
Humans
*Insulin Resistance
Lipoproteins, HDL Cholesterol/blood
Male
Middle Aged
Research Support, Non-U.S. Gov't

Reference

1. DeFronzo RA. Lilly Lecture 1987. The triumvirate: β-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes. 1988. 37:667–687.

2. Warram JH, Martin BC, Krolewski AS, Soeldner JS, Kahn CR. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med. 1990. 113:909–915.

3. Anderson PJ, Critchley JA, Chan JC, Cockram CS, Lee ZS, Thomas GN, et al. Factor analysis of the metabolic syndrome: obesity vs insulin resistance as the central abnormality. Int J Obes Relat Metab Disord. 2001. 25:1782–1788.

4. Despres JP, Lemieux S, Lamarche B, Prud'homme D, Moorjani S, Brun LD, et al. The insulin resistance dyslipidemic syndrome: contribution of visceral obesity and therapeutic implications. Int J Obes Relat Metab Disord. 1995. 19:S76–S86.

5. Tsuruta M, Hashimoto R, Adachi H, Imaizumi T, Nomura G. Hyperinsulinemia as a predictor of hypertension: an 11 year follow up study in Japan. J Hypertens. 1995. 14:483–488.

6. Widen E, Ekstrand A, Saloranta C, Franssila-Kallunki A, Eriksson J, Schalin-Janti C, et al. Insulin resistance in type 2 (non-insulin-dependent) diabetic patients with hypertriglyceridaemia. Diabetologia. 1992. 35:1140–1145.

7. Thomas GN, Hong AW, Tomlinson B, Lam CW, Critchley JA, Sanderson JE, et al. Increasing insulin resistance contributes to worsening glycaemic and lipid profiles in older Chinese subjects. Diabetes Res Clin Pract. 2004. 64:123–128.

8. Geffken D, Keating F, Kennedy M, Cornell E, Bovill E, Tracy R. The measurement of fibrinogen in population-based research. Studies on instrumentation and methodology. Arch Pathol Lab Med. 1994. 118:1106–1109.

9. Clauss A. Rapid physiological method in determination of fibrinogen. Acta Haematol. 1957. 17:237–246.

10. Hirst S, Phillips DI, Vines SK, Clark PM, Hales CN. Reproducibility of the short insulin tolerance test. Diabet Med. 1993. 10:839–842.

11. Park SW, Yun YS, Ahn CW, Nam JH, Kwon SH, Song MK, et al. Short Insulin Tolerance Test (SITT) for determination of in vivo insulin sensitivity-a comparison with euglycemic clamp test. J Korean Diabetes Assoc. 1998. 22:199–208.

12. Shen SW, Reaven GM, Farquhar JW. Comparison of impedance to insulin mediated glucose uptake in normal subjects and in subjects with latent diabetes. J Clin Invest. 1970. 49:2151–2160.

13. Bergman RN, Ider YZ, Bowden CR, Cobelli C. Quantitative estimation of insulin sensitivity. Am J Physiol. 1979. 236:E667–E677.

14. Lundbaek K. Intravenous glucose tolerance as a tool in definition and diagnosis of diabetes mellitus. Br Med J. 1962. 1:1507–1513.

15. Bonora E, Moghetti P, Zancanaro C, Cigolini M, Querena M, Cacciatori V, et al. Estimates of in vivo insulin action in man: comparison of insulin tolerance tests with euglycemic and hyperglycemic glucose clamp studies. J Clin Endocrinol Metab. 1989. 68:374–378.

16. Saad MF, Anderson RL, Laws A, Watanabe RM, Kades WW, Chen YD, et al. A comparison between the minimal model and the glucose clamp in the assessment of insulin sensitivity across the spectrum of glucose tolerance. Insulin Resistance Atherosclerosis Study. Diabetes. 1994. 43:1114–1121.

17. Bergman RN, Prager R, Volund A, Olefsky JM. Equivalence of the insulin sensitivity index in man derived by the minimal model method and euglycemic glucose clamp. J Clin Invest. 1987. 79:790–800.

18. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: A method for quantifying insulin secretion and resistance. Am J Physiol. 1979. 237:E214–E223.

19. Welborn TA, Wearne K. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care. 1979. 2:154–160.

20. Pyorala K. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: Results from two population studies in Finland. Diabetes Care. 1979. 2:131–141.

21. Rossetti L, Giaccari A, DeFronzo RA. Glucose toxicity. Diabetes Care. 1990. 13:610–630.

22. Robinson DC, Anderson L, Bowsher R, Chance R, Dinesen B, Frank B, et al. Report of the American Diabetes Association's task force on standardization of the insulin assay. Diabetes. 1996. 45:242–256.

23. Grulet H, Durlach V, Hecart AC, Gross A, Leutenegger M. Study of the rate of early glucose disappearance following insulin injection: insulin sensitivity index. Diabetes Res Clin Pract. 1993. 20:201–207.

24. Akinmokun A, Selby PL, Ramaiya K, Alberti KG. The short insulin tolerance test for determination of insulin sensitivity. A comparison with the euglycemic clamp. Diabet Med. 1992. 9:432–437.

25. Laakso M, Sarlund H, Mykkanen L. Essential hypertension and insulin resistance in non-insulin-dependent diabetes. Eur J Clin Invest. 1989. 19:518–526.

26. Stewart MW, Laker MF, Dyer RG, Game F, Mitcheson J, Winocour PH, et al. Lipoprotein compositional abnormalities and insulin resistance in type II diabetic patients with mild hyperlipidemia. Arterioscler Thromb. 1993. 13:1046–1052.

27. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities- the role of insulin resistance and the sympathoadrenal system. N Engl J Med. 1996. 334:374–381.

28. Tchernof A, Lamarche M, Prud'homme D, Nadeau A, Moorjani S, Labrie F, et al. The dense LDL phenotype. Association with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men. Diabetes Care. 1996. 19:629–637.

29. Bonser AM, Garcia-Webb P. C-peptide measurement and its clinical usefulness. Ann Clin Biochem. 1981. 18:200–206.

30. DeFronzo RA, Goodman AM. The Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin dependent diabetes mellitus. N Engl J Med. 1995. 333:541–549.

31. Ghazzi MN, Perez JE, Antonucci TK, Driscoll JH, Huang SM, Faja BW, et al. The Troglitazone Study Group. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. Diabetes. 1997. 46:433–439.

32. United Kingdom Prospective Diabetes Study Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes(UKPDS 34). Lancet. 1998. 352:854–865.